Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-02T23:27:27.356Z Has data issue: false hasContentIssue false

P.090 Evaluation of Mutant Alleles of Engrailed and Invected in Drosophila Melanogaster Models of Parkinson Disease

Published online by Cambridge University Press:  05 January 2022

SV Smith
Affiliation:
(Moncton)*
BB Staveley
Affiliation:
(St. John’s)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Parkinson Disease (PD) is a neurodegenerative disorder, resulting in a gradual decline in voluntary movement, where lifespan remains stable. Drosophila melanogaster offer comparable gene sequences to those targeted in PD; among them are two transcription factors, engrailed (en) and invected (inv). Methods: Wild-type homozygous allele Oregon-R(en+, inv+) was compared to heterozygous mutants of en1, en4, en7, en54, en58, invW, inv30, and Df (2R) enEinvE. Nine climbing and aging studies were executed from crosses with w1118(en+, inv+) as the maternal genotype. Results: Independent-samples t-tests were conducted to compare the percent survival (in days). No significant differences were observed between the experimental groups and the control group. A mixed Analysis of Variance was conducted to compare climbing behaviour over time (in weeks) for all nine groups. Both main effects (group, time), and the interaction (group x time) were significant. Post hoc Fisher’s Least Significant Difference tests revealed a significant difference between the control group and en1, en4, en54, invW, and Df (2R) enEinvE groups. Conclusions: These results support the hypothesis that mutations of en, inv, or both will result in a PD phenotype and consequent decreased motor function of D. melanogaster PD models, with or without a significant decrease in lifespan.

Type
Poster Presentations
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation